The structural glycoprotein E rns (an envelope protein with RNase activity) of classical swine fever virus (CSFV) is not well characterized with respect to its antigenic structure and organization.
INTRODUCTION
Classical swine fever virus (CSFV) is an enveloped positivestranded RNA virus (Moennig, 1988) , the causative agent of a highly contagious disease of pigs known as classical swine fever (CSF) with a serious economic consequence. This virus, together with other antigenically and genetically closely related members, bovine viral diarrhea virus (two genotypes: BVDV1 and BVDV2) and border disease virus of sheep (BDV), forms the genus Pestivirus of the family Flaviviridae (Wengler, 1991) . CSFV possesses a 12.5 kb genome encoding a single large polyprotein precursor of approximately 4000 aa. Co-and post-translational cleavage of the polyprotein by cellular and viral proteases yield four structural proteins, C, E rns , E1 and E2, and at least six nonstructural proteins, NS2, NS3, NS4A, NS4B, NS5A and NS5B (Rice & Lindenbach, 2001 ).
Biochemical properties of E rns , one of the three envelope proteins (E rns , E1 and E2) in CSFV, have been studied in some detail. The protein is characterized by a high degree of N-linked glycosylation accounting for about 50 % of the molecular mass of E rns (Rümenapf et al., 1993; Windisch et al., 1996) . This protein contains seven putative N-linked glycosylation sites, five of which have been demonstrated by electrophoretic mobility analysis of the E rns glycoprotein to accept carbohydrate (Sainz et al., 2008) . Addition of oligosaccharides at only one N-linked glycosylation site is important for CSFV virulence (Sainz et al., 2008) . E rns forms a disulfide-bridged homodimer associated with the virion (Langedijk et al., 2002; Thiel et al., 1991) and can be found both on the surface of pestivirus-infected cells and in the culture medium (Rümenapf et al., 1993 (Langedijk et al., 2002) . The C-terminal region of E rns mediates translocation of the full-length protein across eukaryotic cell membranes (Langedijk et al., 2002 by E rns suggests that this glycoprotein is involved in the attachment of the viruses to or the viral entry into susceptible cells . Heparan sulfate glycosaminoglycans act as cell receptors for E rns (Hulst et al., 2000 (Hulst et al., , 2001 . E rns displays homology in two stretches of its amino acid sequence with members of the Rh/T2/S RNase superfamily (Schneider et al., 1993) and contains RNase activity (Hulst et al., 1994; Windisch et al., 1996) , a very unique feature for a viral envelope protein.
The biological function of E rns RNase activity remains to be unveiled. Inactivation of the RNase activity of E rns by mutation gives rise to viruses that are more cytopathic in culture and attenuated in vivo (Hulst et al., 1998; Meyers et al., 1999) . Antibodies that inhibit E rns RNase activity also tend to neutralize virus infectivity (Windisch et al., 1996) . The CSFV E rns also exhibits the ability to induce lymphocyte apoptosis in several species (Bruschke et al., 1997) , although no link between the RNase activity of E rns and cytotoxicity has been reported as seen in other soluble RNases (Schein, 1997) .
E
rns and E2 are two important targets of humoral immune response to CSFV infection. Serological diagnosis of CSF often aims to demonstrate the presence of antibodies to these two glycoproteins (Clavijo et al., 2001; Langedijk et al., 2001; Lin et al., 2005a; Moser et al., 1996; Müller et al., 1996) . Both glycoproteins are capable of conferring protective immunity in pigs Hulst et al., 1993; König et al., 1995; van Rijn et al., 1996) and of inducing virus-neutralizing antibodies (Weiland et al., 1990 (Weiland et al., , 1992 Wensvoort, 1989) . E2 has been studied extensively with regard to epitope characterization of its specific mAbs. Epitope mapping for a number of mAbs to E2 led to defining four antigenic domains A, B, C and D in the N-terminal half of the protein (van Rijn et al., 1992 (van Rijn et al., , 1993 (van Rijn et al., , 1994 Wensvoort, 1989) . A highly conserved linear epitope among pestivirus was identified at the C-terminal region of CSFV E2 (Yu et al., 1996) . Our group has also mapped a 9 aa sequence TAVSPTTLR of E2 (aa 829-837 of the polyprotein) to the epitope recognized by mAb WH303, which has affinity for various CSFV strains, but not other pestiviruses (Lin et al., 2000) . This linear epitope was also confirmed by Zhang et al. (2006) using a phage display peptide library. Knowledge about the mAb WH303 epitope has facilitated the identification of a novel virulence determinant within E2 (Risatti et al., 2006) and has also led to the exploration of a WH303 epitope-based vaccine (Liu et al., 2006a, b) . In contrast, much less is known about the antigenic properties of CSFV E rns . Eleven mAbs against CSFV E rns were established in previous studies (Kosmidou et al., 1995; Weiland et al., 1992) . The epitopes for two of these 11 mAbs, mAb # b4-22 and mAb # 24/16, were mapped to two overlapping sequences 116 YDKNTDVNV 124 (9 aa) and 114 CRYDKNTDVNV 124 (11 aa) on the CSFV E rns , respectively, by using Escherichia coli cell surface display of gene-derived random peptide libraries (Christmann et al., 2001) . Later, a study with the use of a phage display peptide library confirmed the epitopes and further revealed a binding motif 117 DKN 119 for both mAb # b4-22 and mAb # 24/16 (Zhang et al., 2006) . The picture of the E rns epitopes is far from complete and will require more effort to determine. Given that E rns is a glycosylated surface RNase that contributes to CSFV virulence, induction of virus neutralizing antibodies and protective immunity, identification of more epitopes on E rns would not only provide new antigenic and structural insights into the protein, but also the knowledge that may form the basis for identification of virulence determinants and therapeutic drug targets within the protein, rational design of peptide diagnostic reagents, development of live-attenuated virus vaccines and characterization of the biological function of E rns RNase activity.
In this study, we have raised a set of 18 mAbs to the CSFV E rns and defined five clusters of novel linear epitopes within E rns for the majority of these mAbs by using peptide array and random peptide phage display approaches. The implications of these findings are discussed.
RESULTS

Production of mAbs to E rns
Screening for mAb-producing hybridomas from three fusions (one with a CD1 mouse receiving the recombinant E rns aa 27-227 E1 aa 1-7 and two with ND4 mice immunized with the recombinant E rns aa 27-207 ) identified 24 positive monoclonals based on their ability to recognize the immunizing proteins in ELISA. Eighteen of these mAbs belonged to immunoglobulin subclass G1 (M2117, M2159, M2160, M2162, M2163, M2166, M2167, M2168, M2169, M2170, M2172, M2174, M2175, M2176, M2178, M2179, M2180 and M2181); six mAbs were G2b antibodies (M2161, M2164, M2165, M2171, M2173 and M2177) (Fig. 1) . Further analysis of these mAbs by Western blotting (Fig. 1) revealed that six mAbs (M2159, M2160, M2170, M2174, M2179 and M2181) reacted with both the recombinant E rns and E2 polypeptides, presumably through recognition of the N-terminal fusion portion including a 66His tag common to both recombinant proteins. The other 18 mAbs, binding only to the recombinant E rns fragment, were considered E rns -specific and targeted for this epitope mapping study.
Epitope mapping for anti-E rns antibodies using overlapping peptides
Probing of an array of 96 overlapping 12-mer peptides (spanning aa 27-227 of the E rns protein) with the 18 E rnsspecific mAbs revealed that 14 bound to peptide spots and four mAbs (M2117, M2166, M2173 and M2175) showed no reactivity with any 12-mer peptides (Fig. 2) . The sequences of overlapping 12-mer peptides, with the reactivity of these peptides to all 14 anti-E rns mAbs, are presented in Fig. 3 , illustrating the location of linear epitopes dispersed within the E rns protein. In contrast to the majority of the reactive antibodies, M2161 and M2162 recognized two or more sites (epitopes) on E rns . Those 12 mAbs specific for a single epitope can be classified into five epitope-binding groups (I-V), each of which recognized a well-separated, non-overlapping epitope on E rns (Fig. 3) Characterization of the epitopes recognized by anti-E rns antibodies using phage display
To elucidate the critical residues within each of the five epitope groups for antibody recognition, a phage library displaying 12-mer random peptides was screened against one mAb representative from each group, i.e. M2172 (group 1), M2171 (group II), M2165 (group III), M2180 (group IV) and M2176 (group V). Alignment of the 12-mer peptide sequences displayed by selected phage binders with the E rns sequence (Fig. 4) revealed the sequence motif GIWPE in the epitope recognized by M2172 with a strongly conserved Trp 33 residue; M2171 bound to an epitope containing the motif TXXKL with a strongly conserved Leu 71 residue; M2165 recognized the sequence motif VXXQARNXPT with two strongly conserved Gln 127 and Asn 130 residues; and the epitope for M2180 possessed the motif SXXGT with two highly conserved Ser 145 and Gly 148 residues. The critical residues for the epitope recognized by M2176, the only mAb in group V, were not resolved because the biopanning with this mAb failed to recover any binders from the third round. The sequence motifs revealed by the phage display method are very consistent with the epitope core sequences identified by the peptide array.
DISCUSSION
The focus of this study was the investigation into the antigenic sites on the CSFV structural glycoprotein E rns by raising mAbs against the two E. coli expressed E rns fragments and defining the B-cell epitopes recognized by these antibodies. Previously, we have shown by Western blot analysis that these E. coli expressed E rns fragments are recognized by sera from CSFV-infected pigs and we further identified the antigenic regions of E rns for pig antibodies elicited during CSFV infection (Lin et al., 2004) . Here, we reported the generation of a set of 18 mAbs to the CSFV E rns and showed evidence that they recognized linear B-cell epitopes on E rns based on the reactivity of these antibodies with the denatured recombinant E rns on Western blots. Use of an array of overlapping 12-mer peptides has allowed the epitopes for 12 mAbs to be mapped precisely to a high resolution of 6-8 aa, which cluster in five discrete loca- (Figs 3 and 5 ). These mAbs are thus classified into five groups (I-V), each group of which contains the mAbs recognizing identical or near identical core epitopes. Two mAbs (M2161 and M2162) bound to two or more antigenic sites including the group II epitope on E rns , probably due to the presence of more than one hybridoma cell line in the selected clones. The epitopes for four other anti-E rns mAbs (M2117, M2166, M2173 and M2175) could not be mapped using these overlapping 12-mer peptides. One explanation is that other amino acids adjacent to the synthesized peptides may contribute to the binding of these four mAbs to their linear core epitopes. Longer peptides (.12 mer) or recombinant E rns fragments may be necessary for defining antibody-binding sites for these four mAbs. Random peptide phage display with one mAb from each of the groups, except group V, further showed proteins under denaturing conditions by Western blots. Affinity purified recombinant E rns aa 27-207 and E2 (E2AB), both of which share common fusion amino acid sequences at N-and C-terminal ends, were probed with individual mAbs raised against the recombinant E rns fragments. Each lane contains 1 mg purified recombinant protein.
that some residues are strongly conserved within the epitopes and suggested that these residues such as (11 aa) (Christmann et al., 2001; Zhang et al., 2006) and are distinct from the five groups of linear epitopes identified herein (Fig. 5a ). This difference may be encoded by the CSFV strain Alfort/187 genome (Ruggli et al., 1995 ; GenBank accession no. X87939), was synthesized on derivatized cellulose-based membranes. The array was probed with E rns -specific mAbs.
Epitope mapping for mAbs to the CSFV E rns protein explained by the fact that the mAbs described in this study were obtained by immunizing mice with purified E. coli expressed E rns , whereas the two antibodies #b4-22 and mAb # 24/16 reported previously (Kosmidou et al., 1995; Weiland et al., 1992) were derived from mice immunized with a CSFV strain.
Inspection of the location of the newly defined E rns epitopes in the context of a RNase-active site, putative N-linked glycosylation sites, and secondary structure elements (Fig. 5a) Epitope mapping for mAbs to the CSFV E rns protein Fig. 3 . Sequence of CSFV E rns 12-mer peptides and the reactivity of these peptides with anti-E rns mAbs. For each membrane strip, the highest spot colour intensity was arbitrarily set at 100 % reactivity. Five major clusters of linear epitopes (I-V) are depicted by vertical stripe lines. Peptides were synthesized based on the amino acid sequence of E rns deduced from the CSFV strain Alfort/187 genome (GenBank accession no. X87939). mAbs M2117, M2166, M2173 and M2175 showed no reactivity to any of the 12-mer peptides.
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regions that share significant sequence homology with the most conserved parts of members of the Rh/T2/S RNase family (Horiuchi et al., 1988; Schneider et al., 1993) . The group II epitope for M2163, M2168 and M2171 is partially overlapped with the second region. The crystal structure determined for several members of this RNase family (Kurihara et al., 1996; Matsuura et al., 2001; Nakagawa et al., 1999) confirmed that both regions sharing sequence homology with E rns constituted the RNase-active site. The antigenic epitopes of a protein for antibodies are generally present on the surface of a protein (Benjamin et al., 1984) . The mapping data indicate that the RNase-active site of E rns , accessible to the mAbs, is located on the surface of the protein. This supports the 3D structural model of E rns (Langedijk et al., 2002) , showing the presence of the active site in surface-exposed regions. The group III epitope recognized by M2165 and M2177 is located within the loop between helix 6 and helix 7 of the 3D structural model of The E rns sequences were retrieved from GenBank for CSFV strains Alfort/187 (GenBank accession no. X87939), Weybridge (AY940067), 96TD (AY554397), ALD (D49532), Brescia (M31768), BRESCIAX (AY578687), GPE " (D49533), Riems (AY259122), RUCSFPLUM (AY578688) and SXCDK (GQ923951); BVDV1 strains Oregon C24V (AF091605), NADL (NC_001461), Osloss (M96687) and SD1 (M96751); BVDV2 strains JZ05-1 (GQ888686) and XJ-04 (FJ527854); BDV strains X818 (AF037405), BD31 (U70263), BD78 (U18330), and BDV C413 (AF002227). Amino acid residues that match exactly those of the CSFV Alfort/187 E rns are represented by dots. Five groups of CSFV E rns linear epitopes identified in this study are shown in underlined boldface and labelled I-V: group I for M2164, M2169, M2172 and M2178; group II for M2163, M2168 and M2171; group III for M2165 and M2177; group IV for M2167 and M2180; and group V for M2176. The overlapping epitopes recognized by mAb # 24/16 and mAb # b4-22 against the CSFV E rns (Christmann et al., 2001 ) are shown in boldface letters. The two regions of E rns constituting the active site of RNase are indicated by bars and annotated AS (aa 28-40) and AS (aa 71-89). Secondary structure elements based on a 3D structural model of the pestivirus E rns built by homology modelling (Langedijk et al., 2002) are indicated by bars and labelled S1-S5 (strands) and H1-H7 (helices). Seven putative N-linked glycosylation sites (Sainz et al., 2008) are indicated by solid triangles. (b) Location of the five groups (I-V) of linear epitopes on the 3D structure of the pestivirus E rns proposed by Langedijk et al. (2002) . Groups I (yellow), II (magenta), III (cyan), IV (red) and V (blue) epitopes are highlighted.
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Journal of General Virology 91 (Christmann et al., 2001) are present in close proximity within the same loop region. The group IV epitope recognized by M2167 and M2180 is located on helix 7, which is surface-exposed according to the 3D structural model of E rns . The group V epitope recognized by M2176 is located in the loop between helix 7 and strand 3 and partially overlapped with strand 3. The core sequences of all of the identified epitopes, except for the one recognized by group II mAbs, do not contain a putative N-linked glycosylation site. Thus, the mAbs from groups I, III, IV and V are expected to bind to both glycosylated and non-glycosylated forms of E rns . The residue Asn 65 within the group II epitope has been demonstrated to be targeted for glycosylation (Sainz et al., 2008) , which is likely to interfere with the binding of mAbs to the group II epitope within the glycosylated E rns . In fact, this prediction was supported by the experimental data. By performing Western blot analysis of CSFV Alfort/187-infected cell lysates with one representative from each group of mAbs, we demonstrated that M2164 (group I), M2165 (group III), M2180 (group IV) and M2176 (group V), but not M2163 (group II) recognized the glycosylated form of E rns (data not shown).
In ) that reacted with antisera from CSFV-infected pigs (Lin et al., 2004) . Four (II-V) of the five epitopes identified here are located in these antigenic regions, suggesting that mAbs recognizing these four epitopes have the potential to block antisera of CSFV-infected pigs from binding to E rns and could thus be explored as competing reagent antibodies for the serological diagnosis of CSF by developing a mAbbased competitive immunoassay.
Comparison of pestiviral E rns sequences (Fig. 5a ) reveals the epitope specificity of the anti-CSFV E rns mAbs. The group I epitope is strongly conserved among various strains of pestiviruses. This characteristic is not so surprising because this epitope is located within the amino acid sequence forming the RNase-active site of E rns . It is to be expected that mAbs of this group recognize a wide spectrum of pestivirus strains. The core sequence of the group II epitope is highly conserved among various CSFV strains, while there is a substitution of Arg for Lys at position 70 in other pestiviruses. Such substitution has no effect on the binding of the mAb to random peptides displayed by the phage clones (Fig. 4) . Thus, like group I mAbs, group II mAbs are expected to react broadly with various strains of pestiviruses. The group III epitope, highly conserved among CSFV strains, possesses 2 aa residues critical for antibody binding (Gln 127 and Asn 130 ). One of these amino acid residues (Asn 130 ) has been substituted by Asp in BVDV and BDV strains. Although the effect of Asnto-Asp substitution at position 130 on the antibodyantigen reaction remains unknown, this substitution may subtly destroy the ability of group III mAbs to bind BVDV and BDV strains and thus render these antibodies highly specific for CSFV. The group IV epitope is highly conserved among the strains of CSFV and is variable to some degree among strains of BVDV and BDV. This epitope has a binding motif, 145 SXXGT 149 , in which 2 aa residues critical for antibody binding, Ser 145 and Gly 148 , are strongly conserved among pestivirus strains. However, the motif or the epitope core sequence is not well conserved as a whole among strains of BVDV and BDV. This may allow BVDV and BDV strains to escape recognition by group IV mAbs. This group of mAbs is most likely to be CSFVspecific. The group V epitope is strongly conserved among CSFV strains and highly divergent among BVDV1 strains. The mAbs from this group are not expected to recognize BVDV1. The E rns sequences of BVDV2 and BDV strains corresponding to this epitope are relatively conserved with only 1 or 2 aa substitutions compared to CSFV strains. This suggests that the mAbs from this group may bind to BVDV2 and BDV strains, although this remains to be experimentally resolved.
In conclusion, we successfully generated a panel of 18 mAbs to the CSFV E rns , which were either immunoglobulin subclass G1 or G2b. These antibodies allowed us to define five groups of novel discrete linear epitopes on E rns at a high resolution of 6-8 aa using an array of 12-mer peptides and to resolve some residues within the epitopes critical for antibody binding using phage display of random 12-mer peptides. This information has provided new insights into the structure and organization of epitopes on the CSFV E rns protein and valuable epitope information for the development of vaccines, drugs and diagnostic assays for CSFV.
METHODS
Chemicals and bacterial cultures. Nickel-nitrilotriacetic acid (Ni-NTA) agarose was purchased from Qiagen. The protein assay kit was obtained from Bio-Rad. All other chemicals were of commercially available analytical grade. E. coli strains BL21(DE3)/pLysS (Novagen) and ER2738 (New England Biolabs) were cultured in LB broth or on agar plates at 37 uC.
Expression and purification of recombinant E rns and E2
fragments. The expression constructs pET68-131 and pET68-132 (Lin et al., 2004) were used to express two truncated E rns proteins of CSFV strain Alfort/187, E rns aa 27-227 E1 aa 1-7 and E rns aa 27-207 in E. coli BL21(DE3)/pLysS. Each E rns protein fragment has an N-terminal fusion of 49 residues, including a six-histidine tag and an additional C-terminal fusion of eight residues. Recombinant E rns proteins were affinity purified from 2 to 4 l of culture by (Ni-NTA) agarose chromatography as described previously (Lin et al., 2005b) . Soluble refolded E rns fragments were obtained by elution with 200 mM imidazole in Tris-buffer saline following an on-column refolding step with gradual removal of the denaturing agent (urea) in Washing Buffer as suggested by the supplier of Ni-NTA agarose (Qiagen). The 221 aa N-terminal region of E2 protein (E2AB) spanning aa 690-910 of the CSFV strain Alfort/187 polyprotein was expressed from pETE2AB in E. coli BL21(DE3)/pLysS and purified by Ni-NTA agarose chromatography as described previously (Lin et al., 2000) ; this recombinant E2 protein contains N-and C-terminal fusion amino acid sequences commonly shared by the recombinant truncated E rns proteins. The E2 protein was expressed to act as a specificity control for hybridoma screening. Proteins were quantified by using the Bradford method (Bradford, 1976) with BSA as a standard.
Mouse immunization. Refolded recombinant E rns fragments were used for mouse immunization. It should be noted that column refolded proteins have been used in protein crystallography studies (Oganesyan et al., 2005) . Mice were bled at least 1 day prior to immunization to collect pre-immune sera. To select a mouse from a pool of immunized mice for hybridoma fusions, three female CD-1 mice were injected with the recombinant E rns aa 27-227 E1 aa 1-7 , and 10 female BALB/c and 10 female ND4 mice were immunized with the recombinant E rns aa 27-207 . The recombinant E rns aa 27-227 E1 aa 1-7 , in addition to E rns aa 27-207 , was used for mouse inoculations in order to raise mAbs against a near full-length E rns . Each mouse was immunized subcutaneously with 25 mg of the corresponding recombinant protein emulsified with an equal volume of complete Freund's adjuvant (Sigma-Aldrich) on day 0. Two subsequent booster injections with the same amount of immunogens emulsified with incomplete Freund's adjuvant were given intraperitoneally on days 15 and 28 (for CD-1 mice only) or days 28 and 52 for BALB/c and ND4 mice. After resting at least 4 weeks, mice were given a final intravenous injection with 5-25 mg of the recombinant protein and sacrificed within 1 week for fusions. Animal immunization experiments were approved by the Animal Care Committee at the Ottawa Laboratory Fallowfield, Canadian Food Inspection Agency and carried out under the guidelines of the Canadian Council on Animal Care.
Screening and isotyping of anti-E rns mAbs. Fusions were carried out by harvesting spleen cells from three mice each selected from the immunized CD-1, BALB/c and ND4 mouse groups, respectively. The spleen cells from each mouse were fused separately with Sp2/0-Ag14 myeloma cells (Shulman et al., 1978) according to established procedures (Zola, 1987) . Culture supernatants from hybridoma cells were screened for anti-E rns mAbs by ELISA based on the ability of the secreted antibodies to react strongly with immunizing antigens and on lack of reactivity to the recombinant E2AB protein (Lin et al., 2000) . ELISAs were performed using Nunc Microwell plates (VWR) coated with the purified recombinant proteins at 1 mg ml 21 essentially as described previously (Lin et al., 2006) . The subclasses of immunoglobulins (Ig) secreted by hybridoma cell lines were determined as described previously (Lin et al., 2006) .
Affinity purification of antibodies. Ascitic fluids were produced by injecting hybridoma cell lines into mice and used at a 1 : 1 dilution in PBS to purify mAbs by chromatography on a column (5 ml) of GammaBind G Sepharsoe (GE Healthcare). Bound antibodies were eluted with 0.1 M glycine/HCl (pH 2.5) and immediately neutralized to ypH 7.5 with 1 M Tris/HCl (pH 9.1). The concentration of purified IgG antibodies was determined by measuring absorbance at 278 nm with the absorption coefficient of 1.35 ml mg 21 cm 21 .
Phage display. The PhD-12 phage display peptide library (New England Biolabs), expressing random 12-mer linear peptides fused to the N terminus of the minor coat protein III (pIII) of M13 phage, was biopanned against anti-E rns mAbs essentially according to the supplier's instructions. Briefly, one well of a Linbro 12-well tissue culture plate was coated with 1 ml of a purified mAb (100 mg ml 21 ) and incubated with 1610 11 phages in Tris buffered saline (pH 7.5) containing 0.1 % (v/v) Tween 20. Bound phages were eluted with 1 ml 0.2 M glycine/HCl (pH 2.2) containing 1 mg BSA ml 21 and immediately neutralized with 150 ml 1 M Tris/HCl (pH 9.1). Eluted phages were amplified in E. coli ER2738 and harvested by precipitation with 1/6 volume of 20 % (w/v) polyethylene glycol containing 2.5 M NaCl for further panning. After three rounds of biopannings, individual phage clones were amplified and analysed to confirm the binding specificity by phage ELISA using 96-well MaxiSorp plates (VWR) coated with either specific anti-E rns mAbs or an irrelevant mAb (100 ml per well, 100 mg ml 21 ). Bound phages were detected with an HRP-conjugated anti-M13 mAb (GE Healthcare) at 1 : 5000 dilution. For each anti-E rns mAb, at least 10 amplified phage clones were selected, based on their ability to react specifically with the antibody, for the extraction of single-stranded phage DNA with iodide buffer (10 mM Tris/HCl, pH 8.0, 4 M NaI, 1 mM EDTA). The inserted portions of phage DNA were sequenced with the 296 gIII sequencing primer 59-CCCTCATAGTTAG-CGTAACG-39 and used to deduce the amino acid sequences of encoded 12-mer peptides. The peptide sequences were aligned with the amino acid sequence of E rns using the MEGALIGN module of Lasergene (DNASTAR).
Peptide arrays. A set of 96 overlapping peptides of 12 aa, shifted by two residues, spanning aa 27-227 of the E rns protein encoded by the CSFV strain Alfort/187 genome (Ruggli et al., 1995 ; GenBank accession no. X87939), was synthesized as an array on derivatized cellulose-based membranes (Intavis AG) by the Peptide Array Facility of the Brain Research Centre of the University of British Columbia (Vancouver, British Columbia, Canada) using SPOT technology (Hilpert et al., 2007; Winkler & Campbell, 2008) . The membraneimmobilized peptides were probed with an individual mAb tissue culture fluid at 1 : 25 dilution in PBS (pH 7.2) containing 0.2 % (v/v) Tween 20, 5 % (w/v) sucrose and 4 % (w/v) skimmed-milk powder. Captured antibodies were detected using HRP-conjugated goat antimouse IgG (Jackson ImmunoResearch Laboratories) at 1 : 1000 dilution and an HRP colour development substrate kit (Bio-Rad) according to the manufacturer's instructions. The membranes were regenerated for another round of probing by treatment with 8 M urea containing 1 % (w/v) SDS overnight followed by 90 % (v/v) trifluoroacetic acid for at least 1 h and then 100 % methanol three times for 10 min each.
Western blotting. Purified recombinant E rns aa 27-207 and E2 (E2AB) were analysed by SDS-PAGE followed by Western blots probed with mAbs. SDS-PAGE was carried out by the method described by Laemmli (1970) , using a 4 % stacking gel and a 12 % resolving gel in a Bio-Rad minigel apparatus (Bio-Rad). Binding of mAbs to denatured recombinant E rns and E2 proteins was detected using the Western blotting procedure described previously (Lin et al., 2006) with mAbcontaining hybridoma cell culture fluids at a dilution of 1 : 25.
